Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation
- Authors: Abdullaev S.P1, Mirzaev KB1, Sychev DA1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 91, No 8 (2019)
- Pages: 22-27
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33585
- DOI: https://doi.org/10.26442/00403660.2019.08.000379
- ID: 33585
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Sh P Abdullaev
Russian Medical Academy of Continuous Professional Educationм.н.с. отд. молекулярной медицины НИИ молекулярной и персонализированной медицины; ORCID: 0000-0001-9001-1499 Moscow, Russia
K B Mirzaev
Russian Medical Academy of Continuous Professional Education
Email: karin05doc@yandex.ru
к.м.н., зав. отд. персонализированной медицины НИИ молекулярной и персонализированной медицины; ORCID: 0000-0002-9307-4994 Moscow, Russia
D A Sychev
Russian Medical Academy of Continuous Professional Educationд.м.н., проф., член-корр. РАН, проф. РАН; ректор ФГБОУ ДПО «РМАНПО»; ORCID: 0000-0002-4496-3680 Moscow, Russia
References
- https://www.who.int/cardiovascular_diseases/en/ (Ссылка активна на 15.04.2019).
- Laslett L.J, Alagona P.Jr, Clark B.A 3rd, Drozda J.P. Jr, Saldivar F, Wilson S.R, Poe C, Hart M. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S1-49. doi: 10.1016/j.jacc.2012.11.002
- Kim M.H, Johnston S.S, Chu B.C, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circulation: Cardiovasc Qual Outcom. 2011;4:313-20. doi: 10.1161/CIRCOUTCOMES.110.958165
- Patel N.J, Deshmukh A, Pant S, Singh V, Patel N, Arora S, Shah N, Chothani A, Savani G.T, Mehta K, Parikh V, Rathod A, Badheka A.O, Lafferty J, Kowalski M, Mehta J.L, Mitrani R.D, Viles-Gonzalez J.F, Paydak H. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129(23):2371-9. doi: 10.1161/CIRCULATIONAHA.114.008201
- Connolly S.J, Ezekowitz M.D, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly P.A, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis B.S, Darius H, Diener H.C, Joyner C.D, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561
- Shi J, Wang X, Nguyen J.H, Bleske B.E, Liang Y, Liu L, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76-84. doi: 10.1016/j.bcp.2016.09.003
- Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz M.D, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen A.C, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233
- Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia G.L, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1-5. doi: 10.1016/j.thromres.2016.05.025
- Johnson J.A, Caudle K.E, Gong L, Whirl-Carrillo M, Stein C.M, Scott S.A, Lee M.T, Gage B.F, Kimmel S.E, Perera M.A, Anderson J.L, Pirmohamed M, Klein T.E, Limdi N.A, Cavallari L.H, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharm Ther. 2017;102(3):397-404. doi: 10.1002/cpt.668
- Ramsey L.B, Johnson S.G, Caudle K.E, Haidar C.E, Voora D, Wilke R.A, Maxwell W.D, Mc Leod H.L, Krauss R.M, Roden D.M, Feng Q, Cooper-De-Hoff R.M, Gong L, Klein T.E, Wadelius M, Niemi M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin - induced myopathy: 2014 update. Clin Pharm Ther. 2014;96(4):423-8. doi: 10.1038/clpt.2014.125
- Scott S.A, Sangkuhl K, Stein C.M, Hulot J.S, Mega J.L, Roden D.M, Klein T.E, Sabatine M.S, Johnson J.A, Shuldiner A.R; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-23. doi: 10.1038/clpt.2013.105
- You J.H. Pharmacogenetic - guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost - effectiveness analysis. Pharmacogenet Genom. 2014;24(1):6-14. doi: 10.1097/FPC.0000000000000014
- Eckman M.H, Rosand J, Greenberg S.M, Gage B.F. Cost - effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73-83. doi: 10.7326/0003-4819-150-2-200901200-00005
- Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos J.G.S, Martínez-González L.J, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali B.R, Wordsworth S, Dávila-Fajardo C.L, Katsila T, Patrinos G.P, Mitropoulou C. Cost - effectiveness analysis of pharmacogenomics - guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. Pharmacogenomi J. 2019. [Epub ahead of print]. doi: 10.1038/s41397-019-0069-1
- Verbelen M, Weale M.E, Lewis C.M. Cost - effectiveness of pharmacogenetic - guided treatment: are we there yet? Pharmacogenom J. 2017;17(5):395-402. doi: 10.1038/tpj.2017.21
- Sychev D.A, Abdullaev S.P, Mirzaev K.B, Ryzhikova K.A, Shuyev G.N, Sozaeva Z.A, Grishina E.A, Mammaev S.N, Gafurov D.M, Kitaeva E.Y, Shprakh V.V, Suleymanov S.S, Bolieva L.Z, Sozaeva M.S, Zhuchkova S.M, Gimaldinova N.E, Sidukova E.E, Asoskova A.V, Mumladze R.B. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi - ethnic analysis. Mol Biol Rep. 2019 [Epub ahead of print]. doi: 10.1007/s11033-019-04722-w
- Hernandez I, Baik S.H, Piñera A, Zhang Y. Risk of Bleeding With Dabigatran in Atrial Fibrillation. JAMA Intern Med. 2015;175(1):18-24. doi: 10.1001/jamainternmed.2014.5398
- Инструкция по медицинскому применению Прадакса®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bb76178c-cf95-4cbd-9883-6ba08ccb508d&t (Ссылка активна на 23.04.2019).
- Eikelboom J.W, Wallentin L, Connolly S.J, Ezekowitz M, Healey J.S, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser S.H, Diener H.C, Franzosi M.G, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran сompared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long - term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747
- https://www.medlux.ru/ (Ссылка активна на 15.04.2019).
- https://apteka.ru/ (Ссылка активна на 15.04.2019).
- Тарифное соглашение на оплату медицинской помощи, оказываемой по территориальной программе обязательного медицинского страхования города Москвы на 2019 год от 27 декабря 2018 года. http://www.mgfoms.ru/medicinskie-organizacii/tarifi (Ссылка активна на 22.04.2019).
- Ягудина Р.И., Куликов А.Ю., Метелкин И.А. Методология анализа «затраты - эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика. 2012;4(5):3-8.